Table of Content


1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious Diseases and Cancer
4.2.2 Rising Demand for Point-of-care Diagnostics
4.2.3 Recent Advancements in Technology and Pharmacogenomics
4.3 Market Restraints
4.3.1 Uncertain Reimbursement Scenario
4.3.2 Need for High-complexity Testing Centers
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Infectious Diseases
5.1.2 Oncology
5.1.3 Hematology
5.1.4 Prenatal Testing
5.1.5 Endocrinology
5.1.6 Other Applications
5.2 By Technology
5.2.1 PCR
5.2.2 Genetic Sequencing
5.2.3 Hybridization
5.2.4 Microarray
5.3 By End-User
5.3.1 Hospitals
5.3.2 Homecare
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bayer AG
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Bio-Rad Laboratories
6.1.5 Danaher Corporation
6.1.6 BioMerieux
6.1.7 Agilent Technologies
6.1.8 OraSure Technologies Inc.
6.1.9 Thermo Fisher Scientific (Qiagen NV)


7 MARKET OPPORTUNITIES AND FUTURE TRENDS